David I Smith received his B.S. in Mathematics and Molecular Biology from the University of Wisconsin in Madison. He then received his Ph.D. for the Department of Biochemistry also at the University of Wisconsin in Madison. After several postdoctoral positions he got his first ... academic appointment at Wayne State University. In 1996 he joined the Mayo Clinic in the Department of Laboratory Medicine and Pathology as Professor and Consultant. He was also appointed as the head of the Cancer Genetics Program for the Mayo Clinic Cancer Center. His research focuses on the role that the common fragile sties play in cancer development. His laboratory also works on the various roles that human papillomavirus plays in the development of different cancers. Dr. Smith is also the Chairman of the Technology Assessment Group for the Mayo Clinic Center for Individualized Medicine. The responsibility of this group is to evaluate new technologies for their potential impact on research and its' clinical translation. His laboratory utilizes next generation sequencing to characterize the molecular alterations that occur during the development of cancer. They also have been using the powerful technique of mate-pair next generation sequencing (MP-Seq) to characterize the physical status of HPV in different HPV-driven cancers.

Dr. Sarah H. Elsea is an Associate Professor of Molecular and Human Genetics at Baylor College of Medicine and is Senior Division Director of Biochemical Genetics at Baylor Genetics. Dr. Elsea earned a B.S. in chemistry from Missouri State University and Ph.D. in biochemistry ... from Vanderbilt University. She completed postdoctoral training in molecular and biochemical genetics at Baylor College of Medicine and is a board-certified geneticist through the American Board of Medical Genetics and Genomics. Her research is focused on the discovery, pathomechanisms, diagnosis, and treatment of rare disease, particularly neurodevelopmental disorders that are complicated by circadian rhythm abnormalities and metabolic disturbances. She has been instrumental in the push for precision medicine with the development of clinical metabolomics for the diagnosis of rare disease, particularly coupled with whole exome data. She is a member of several professional societies and has authored more than 80 scientific and lay articles.

Tatjana is an immunologist with more than two decades of experience working at biotech and pharma companies from start-ups to large global corporations ( Pfizer,Inc. being the latest), contributing significantly to team efforts and successes of more than thirty early and clinical ... stage programs and several commercial products and biosimilars.

Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ... breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.